Pioglitazone Tablets – Manufacturer & Exporter India

1. Product Introduction

Pioglitazone is an oral thiazolidinedione (TZD) medicine used to improve glycemic control in adults with type 2 diabetes when appropriate alongside diet and exercise. It improves insulin sensitivity through activation of peroxisome proliferator-activated receptor gamma (PPAR-γ). It is not used to treat type 1 diabetes or diabetic ketoacidosis.

Healthy Life Pharma Pvt. Ltd. and Healthy Inc are identified in the supplied product information as manufacturer and exporter respectively. Site certifications and export credentials require documentary confirmation.

2. Product Specifications

Therapeutic class: Antidiabetic / Thiazolidinedione. SKU: Pioglitazone Tablets. The 45 mg single-ingredient strength mentioned in the description is not supported by the supplied composition list and is not represented as a confirmed variant.

3. Manufacturing Technology

Manufacture of low-dose pioglitazone tablets requires controlled blending, content uniformity and suitable disintegration and dissolution performance. The single-ingredient uncoated tablets and the pioglitazone/metformin film-coated combination are separate formulations requiring their own specifications, stability programs and regulatory approvals.

Specific equipment, granulation methods, humidity controls, packaging materials and manufacturing capabilities must be verified against approved site and product records before publication.

4. Quality Assurance

Product-specific quality controls may include identity, assay, dosage-unit uniformity, dissolution, related substances and stability testing according to the applicable approved IP specification and registration dossier. Numerical acceptance limits should be taken from approved methods rather than assumed.

For the combination product, testing must cover both pioglitazone and metformin, including appropriate release and impurity assessments.

5. Mechanism and Therapeutic Use

Pioglitazone is a PPAR-γ agonist that increases insulin sensitivity in peripheral tissues and helps reduce blood glucose in people with type 2 diabetes. It is sometimes used alone or with other glucose-lowering medicines according to local approvals and individual clinical assessment.

It does not provide immediate glucose correction and is not appropriate for diabetic ketoacidosis. Benefits must be weighed against risks including fluid retention and heart failure.

6. Export and Regulatory Support

International supply depends on approved product registrations, import requirements, correct labeling and available manufacturing authorizations. Buyers should request current certificates of analysis, stability documentation, dossiers and product-specific packaging specifications.

Claims regarding WHO-GMP certification, Star Export House status, CTD/ACTD dossiers, COPP, export markets, shelf life or shipment terms require verification before commercial use.

7. Frequently Asked Questions

Which pioglitazone strengths are listed? Uncoated IP tablets equivalent to pioglitazone 15 mg and 30 mg.

Is a combination product included? Yes, a separate film-coated tablet containing pioglitazone 15 mg and metformin hydrochloride 500 mg.

Is 45 mg available? It is mentioned in the supplied marketing description but not confirmed by the provided composition list.

Can pioglitazone worsen heart failure? Yes. It can cause or worsen fluid retention and heart failure; suitability requires clinician assessment.

8. Dosage and Administration

Use only as directed by a licensed clinician and the approved local product label. The starting dose and any adjustments depend on clinical status, glucose response, other medicines and contraindications. Do not apply a single dosing instruction to both plain pioglitazone and the pioglitazone/metformin combination.

For combination tablets, metformin-specific precautions, including kidney-function assessment and lactic acidosis risk, must also be considered. Do not alter therapy without professional advice.

9. Side Effects and Precautions

Important warning: Pioglitazone can cause or exacerbate congestive heart failure. Watch for rapid weight gain, swelling or shortness of breath and seek prompt medical assessment. Use is contraindicated in certain heart-failure populations under applicable labeling.

Other concerns include weight gain, edema, increased fracture risk (particularly in women), possible bladder-cancer-related labeling precautions, liver injury and hypoglycemia when combined with insulin or insulin secretagogues. Pregnancy and other special-population decisions require medical advice.

The pioglitazone/metformin combination has additional metformin risks, including lactic acidosis in susceptible patients. Review the complete approved prescribing information.

10. Storage Instructions

Store according to the approved product label in original packaging and protect from conditions specified by the manufacturer. Keep out of reach of children. Exact temperature limits, shelf life and pack configuration require confirmation from validated stability and packaging data.